OKYO Pharma (FRA:OK10) Other Current Liabilities: €0.23 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OK10 OKYO Pharma Ltd FRA:OK10
24 GF Score
Price €1.36
! 2 Warning Signs
View Full Analysis

What is OKYO Pharma Other Current Liabilities?

OKYO Pharma FRA:OK10 24 Other Current Liabilities is €0.23 Mil as of Mar. 2026. GuruFocus rates FRA:OK10 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

OKYO Pharma's other current liabilities for the quarter that ended in Mar. 2026 was €0.23 Mil.

OKYO Pharma's quarterly other current liabilities declined from Mar. 2025 (€0.18 Mil) to Sep. 2025 (€-0.00 Mil) but then increased from Sep. 2025 (€-0.00 Mil) to Mar. 2026 (€0.23 Mil).

OKYO Pharma's annual other current liabilities increased from Mar. 2024 (€0.00 Mil) to Mar. 2025 (€0.18 Mil) and increased from Mar. 2025 (€0.18 Mil) to Mar. 2026 (€0.23 Mil).

OKYO Pharma Other Current Liabilities Related Terms

OKYO Pharma Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma Other Current Liabilities Chart

OKYO Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.18 0.23

OKYO Pharma Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.18 -0.00 0.23
FRA:OK10
24GF Score
OKYO Pharma Ltd FRA:OK10
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OKYO Pharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €0.23 Mil mean?
OKYO Pharma (FRA:OK10) has a Other Current Liabilities of €0.23 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OKYO Pharma.
Is OKYO Pharma's Other Current Liabilities too high?
OKYO Pharma's current Other Current Liabilities is €0.23 Mil. Overall, OKYO Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's Other Current Liabilities compare to ALPS and CGTX?
OKYO Pharma's Other Current Liabilities of €0.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OKYO Pharma. OKYO Pharma's current Other Current Liabilities is €0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (FRA:OK10) has a current Other Current Liabilities of €0.23 Mil. The current Other Current Liabilities is €0.23 Mil. OKYO Pharma's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For OKYO Pharma (FRA:OK10), the current Other Current Liabilities is €0.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Other Exchanges OKYO:USA
Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
24GF Score

Get the complete analysis for FRA:OK10

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.36
Price